It is well documented that CAR-T cells represent eligible patients with R/R CD19+ B-lineage ALL and DBCL who lack other therapeutic options and an opportunity to obtain a further clinical response and a potential cure [20,21]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.